medicaid coverage glp 1 What to Know About the BALANCE Model for GLP-1s in Medicare and and the Medicare GLP-1 Bridge Doctors call Ozempic a miracle

The results of the TRANSCEND-T2D-1 trial, published in March 2026, showed that participants with type 2 diabetes mellitus, who took retatrutide 12mg, lost an average of 16.8% of their body weight at 40 weeks

If you maintain the positive changes in diet, exercise, and overall wellness that contributed to your weight loss, its possible to keep the weight off after stopping the medication

One clarification first: Ozempic is approved for type 2 diabetes, not for weight management

Heres how Found measures up

These next-generation medications would be designed from the ground up to target addiction pathways, rather than being repurposed from diabetes and obesity treatments

Retatrutide and Tirzepatide | Side Effects and Safety Research into tirzepatide and retatrutide has yielded substantial insights into their potential side effects, with gastrointestinal issues being the most frequently reported across studies